Meet our Keynote and Plenary speakers
Keynote speaker
Saturday 21 September, 15.15-16.00
Yasmin Hurd, USA
The vulnerable brain: pathways to and from addiction
Yasmin Hurd is the director of the addiction institute within the Mount Sinai behavioral health system as well as the Ward Coleman chair of translational neuroscience and professor of psychiatry and neuroscience at the Icahn School of medicine at Mount Sinai in New York. Hurd’s translational research examines the neurobiology of drug abuse and related psychiatric disorders. Her research exploring the neurobiological effects of cannabis and heroin has significantly shaped the field. Using multidisciplinary research approaches, her research has provided unique insights into the impact of developmental cannabis exposure and epigenetic mechanisms underlying the drug’s protracted effects. Based on Hurd’s high impact accomplishments and her advocacy of drug addiction education and health, she was inducted into both the National Academy of medicine and the National Academy of science, complementing other honours she has received in the field.
Plenary Speakers
We will again have Plenary Lectures as part of the scientific programme. Our confirmed speakers are:
Sunday 22 September, 10.20-11.05
Erin Schuman, Germany
PL01 — Brain Prize Lecture — Protein supply and demand at synapses
Erin Schuman was born in California. She did her undergraduate, graduate and postdoctoral studies at the University of Southern California, Princeton and Stanford, respectively. In 1993, she joined Caltech’s biology faculty and was an HHMI investigator from 1997-2009. In 2009, she moved with her husband Gilles Laurent to Frankfurt, Germany to found the new Max Planck Institute for brain research. She is a member of EMBO, and the German and U.S. National Academies of science. In 2020 she was awarded the Louis-Jeantet Prize for edicine and the FENS-Kavli-ALBA Diversity Prize. In 2022 and 2023, she was awarded the EMBO-FEBS Women in Science prize, the Rosenstiel Prize and the Brain Prize. Erin has a long standing interest in the molecular and cell biological processes that control protein synthesis and degradation in neurons. Following on the lab’s initial discovery in 1996 that proteins made locally in dendrites are required for synaptic plasticity, they have pursued the identification of the mRNA and ribosome population present in neuronal dendrites and axons- with the goal of understanding protein supply and demand at synapses.
Erin Schuman won the 2023 Brain Prize together with Michael Greenberg and Christine Holt for their ground-breaking discoveries showing how the synthesis of new proteins is triggered in different parts of the neuron, thereby guiding brain development and plasticity in ways that shape our lifelong behaviour. The world’s largest brain research prize is awarded annually by the Lundbeck Foundation. Each year, they award 10 million DKK (approx. 1,3 million EUR) to one or more neuroscientists who have made a ground-breaking impact on brain research. The Brain Prize has been awarded to 44 scientists from 11 different countries. More info
Sunday 22 September, 16.40-17.25
Elias Eriksson, Sweden
PL02 — ECNP Neuropsychopharmacology Award Lecture
The efficacy and mechanisms of action of SSRIs – lessons learnt from premenstrual dysphoric disorder and depression
Elias Eriksson is Med Dr and professor of pharmacology at the University of Gothenburg in Sweden. His current research is focused on the efficacy and mechanisms of action of SSRIs for depression, anxiety disorders, and premenstrual dysphoric disorder; novel ways to modulate the output from dopaminergic synapses; and novel ways to counter motor fluctuations in levodopa-treated patients with Parkinson´s disease.
Elias is the recipient of the 2024 ECNP Neuropsychopharmacology Award, in recognition of his achievements in advancing the science of serotonin reuptake inhibitors (SSRIs) for the treatment of panic disorder, premenstrual dysphoric disorder and depression.
Read the press release
The ECNP Neuropsychopharmacology Award recognises exceptional research achievements in applied and translational neuroscience.
The award is granted each year, alternating between pre-clinical and clinical research. The 2024 award is in clinical research. More about this award.
Monday 23 September, 10.20-11.05
Siri Leknes, Norway
PL03 — How opioids shape our feelings: sorting facts from myths
Siri Leknes is a professor of social and affective neuroscience at the University of Oslo, Norway, and senior researcher at Oslo University Hospital. She completed her D.Phil. at Oxford, United Kingdom, and postdoctoral research at Gothenburg University, Sweden.
L.A.B. (Leknes Affective Brain) lab specialises in drug studies, charting how the brain’s neurochemical systems shape hedonic feelings, decisions and behaviour. Leknes is currently funded by an ERC grant to study state-dependent effects of opioids and their relation to social support, stress and dopamine. In addition, L.A.B lab conducts clinical research, studying mood, stress and pain in groups treated with opioid agonists and antagonists.
Leknes’ work on the benefits of acute pain was awarded The Daniel M. Wegner Theoretical Innovation Prize in social/personality psychology. She has served as associate editor for social cognitive affective neuroscience and is now associate editor for pain. She is also the President of the Society for social neuroscience.
She recently spoke about her work to ECNP press officer, Tom Parkhill.
Read the interview
Monday 23 September, 16.40-17.25
Ivan de Araujo, Germany
PL04 — Brain-body regulation of health and disease
Ivan De Araujo studied philosophy at the University of Brasilia, followed by postgraduate studies in the field of artificial intelligence at the University of Edinburgh. He received his doctorate in experimental psychology and medical imaging from the University of Oxford. As a postdoctoral researcher in neurobiology at Duke University Medical Center, he identified brain neural networks that interact with the digestive tract. He went on to direct the neurobiology of feeding laboratory at Pierce Labs at Yale University for more than a decade before moving to the Icahn School of medicine at Mount Sinai Hospital in 2018. Ivan is now the director at the Max Planck Institute for biological cybernetics and scientific member of the Max Planck Society. His research focuses on understanding how the numerous processes in the human body are recorded and controlled by the brain and how these in turn influence body physiology, especially the gastrointestinal tract .
Tuesday 24 September, 10.10-10.55
Ann M. Graybiel, USA
PL05 — The basal ganglia and the decision to act
Ann M. Graybiel is an institute professor at the Massachusetts Institute of technology, where she and her laboratory are actively investigating neural circuits related to the basal ganglia and to a range of neurologic and neuropsychiatric disorders. Her work is centered on understanding the functions of circuits leading from mood-related parts of the frontal neocortex through the striatum to the dopamine-containing neurons of the midbrain. This work took its origin in her discovery of neurochemically distinct compartments in the striatum, which she named ‘striosomes’. These are now known to provide all or nearly all striatal input to the dopamine-containing neurons of the midbrain. These circuits strongly bias decision-making made under motivationally challenging conditions, as though inducing optimistic or pessimistic state changes. They can strongly modulate responses to stress and levels of engagement across age, and levels of reinforcement-based learning. Her group is now harnessing molecular and genetic markers in functional work of these and related circuits of the striatal matrix, with the goal of contributing to clinical medicine as well as to fundamental understanding of the brain.
Tuesday 24 September, 14.00-14.45
Katharina Domschke, Germany
PL06 — Epigenetics, stress and the neurobiology of anxiety and affective disorders
Katharina Domschke, MA, MD, PhD is full professor and chair of the department of psychiatry and psychotherapy, University of Freiburg, Germany, since 2016. Her clinical focus is on the treatment and prevention of anxiety, stress-related and affective disorders. Scientifically, Katharina is a renowned expert in genetics, epigenetics, imaging genetics and pharmacogenetics in the targeted treatment and prevention of anxiety, stress-related and affective disorders as reflected by to date ~450 publications in international journals and an h-index of 60. She has received funding from the EU, the German Research Foundation (DFG) and the German Ministry of research and education (BMBF) and is a full member of ACNP, ECNP, ISPG, SOBP and the German National Academy of science Leopoldina. Katharina serves on the editorial boards of 15 international journals. Her work has been recognised by e.g. the WFSBP Research Award, the WPA Fellowship Award and the ECNP Fellowship Award.
